Expanding Horizons in Cancer Research: Phio Pharmaceuticals Corp.’s Latest Developments

Breaking News: Phio Pharmaceuticals Corp.’s Strategic Move

Marlborough, Massachusetts–(Newsfile Corp. – December 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 437,192 shares of its common stock at a purchase price of $2.635 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 437,192 shares of common stock.

Phio Pharmaceuticals Corp. is making waves in the field of cancer research with its cutting-edge gene silencing technology. By enhancing the body’s immune cells’ ability to combat cancer cells, the company is paving the way for more effective and targeted cancer treatments.

The recent announcement of the purchase and sale of common stock signifies a significant milestone for Phio Pharmaceuticals Corp. This strategic move not only demonstrates confidence in the company’s innovative approach but also provides crucial funding for future research and development initiatives.

With the issuance of unregistered warrants through a concurrent private placement, Phio Pharmaceuticals Corp. is positioning itself for continued growth and progress in advancing the field of oncology. Investors and stakeholders alike are closely watching the company’s evolution as it continues to make strides in the fight against cancer.

Impact on Individuals

For individuals, Phio Pharmaceuticals Corp.’s latest developments offer hope for improved cancer treatment options. By enhancing the body’s immune response to cancer cells, patients may have access to more personalized and effective therapies in the future. This groundbreaking research has the potential to positively impact the lives of those affected by cancer, providing new avenues for treatment and care.

Global Implications

Phio Pharmaceuticals Corp.’s advancements in cancer research have far-reaching implications on a global scale. By developing innovative therapies that leverage gene silencing technology, the company is contributing to the ongoing effort to combat cancer worldwide. The insights gained from Phio Pharmaceuticals Corp.’s research have the potential to revolutionize cancer treatment strategies and improve outcomes for patients across the globe.

Conclusion

Phio Pharmaceuticals Corp.’s recent strategic move marks a significant milestone in the field of cancer research. With its focus on enhancing the body’s immune response to cancer cells, the company is at the forefront of innovative therapies that have the potential to transform cancer treatment as we know it. As Phio Pharmaceuticals Corp. continues to push boundaries and achieve groundbreaking results, the future of cancer care looks promising and full of possibilities.